Abstract

Early detection of pancreatic ductal adenocarcinoma (PDAC) in the general population is difficult due to unknown clinical characteristics. This study was conducted to clarify the factors associated with early stage PDAC. Well-known symptoms and factors associated with PDAC were classified into clinical indicators, risk factors, and imaging findings concomitant with early stage PDAC. To analyze these factors for the detection of patients with early stage PDAC compared to patients without PDAC, we constructed new diagnostic strategies. The factors of 35 patients with early stage PDAC (stage 0 and IA) and 801 patients without PDAC were compared retrospectively. Clinical indicators; presence and number of indicators, elevated pancreatic enzyme level, tumor biomarker level, acute pancreatitis history, risk factors; familial pancreatic cancer, diabetes mellitus, smoking history, imaging findings; presence and number of findings, and main pancreatic duct dilation were significant factors for early stage PDAC detection. A new screening strategy to select patients who should be examined by imaging modalities from evaluating clinical indicators and risk factors and approaching a definitive diagnosis by evaluating imaging findings had a relatively high sensitivity, specificity, and areas under the curve of 80.0%, 80.8%, and 0.80, respectively. Diagnosis based on the new category and strategy may be reasonable for early stage PDAC detection.

Highlights

  • Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with a 5 year overall survival rate of

  • This study aimed to classify well-known clinical symptoms, risk factors, and indirect imaging findings associated with PDAC to establish a new screening strategy for detecting early stage PDAC in daily outpatients

  • All early stage PDACs were detected as mass lesions or on the basis of indirect imaging findings (MPD dilation and pancreatic cyst) by endoscopic ultrasound (EUS) and surgical resection

Read more

Summary

Introduction

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with a 5 year overall survival rate of

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call